MedeliX
Start asking

atezolizumab

Tecentriq · ATC code L01XC32

Key facts
Active substance
atezolizumab
ATC code
L01XC32
Authorisation
centrally authorised across the EU (EMA)
Dosage forms
Tecentriq 840 mg concentrate for solution for infusion / Tecentriq 1 200 mg concentrate for solution for infusion · Tecentriq 1 875 mg solution for injection
Marketing authorisation holder
Roche Registration GmbH
Information as of
2026-10-27

Key facts

Atezolizumab is a monoclonal antibody against PD-L1 (immune checkpoint inhibitor). It is used in several cancers, including urothelial carcinoma and non-small cell lung cancer (NSCLC).

What it is used for

  • Locally advanced or metastatic urothelial carcinoma in adults (monotherapy, after platinum-containing chemotherapy or if cisplatin-ineligible with PD-L1 ≥ 5%)
  • Adjuvant treatment of early-stage NSCLC after complete resection and platinum-based chemotherapy, high risk of recurrence, PD-L1 ≥ 50% (not EGFR-mutant/ALK-positive)
  • First-line metastatic non-squamous NSCLC in combination with bevacizumab, paclitaxel and carboplatin, or with nab-paclitaxel and carboplatin
  • Further indications (including triple-negative breast cancer) are in the full text

Dosing

  • Intravenous (Tecentriq 840 mg/1,200 mg concentrate): 840 mg every 2 weeks, or 1,200 mg every 3 weeks, or 1,680 mg every 4 weeks
  • Subcutaneous (Tecentriq 1,875 mg solution for injection): 1,875 mg every 3 weeks; patients can switch between intravenous and subcutaneous use
  • Duration by indication: until disease progression or unmanageable toxicity; adjuvant NSCLC for 1 year
  • In combination therapy, atezolizumab is given first on the same day; partner-drug schedules are in the full text
  • Patient selection by PD-L1 expression with a validated test where the indication requires it

Contraindications

  • Hypersensitivity to atezolizumab or any excipient

Important warnings

  • Immune-mediated adverse reactions, possibly affecting more than one body system and occurring after the last dose; withhold and give corticosteroids according to severity
  • Permanently discontinue for recurrent Grade 3 and any Grade 4 immune-mediated reactions (except endocrinopathies controlled with replacement hormones)
  • Taper corticosteroids over ≥ 1 month after improvement to Grade ≤ 1
  • Traceability: record product name and batch number

Side effects

  • Monotherapy, most common: fatigue (29.3%), decreased appetite, rash, nausea, cough, diarrhoea, pyrexia, dyspnoea, arthralgia
  • In combination, most common: anaemia (36.8%), neutropenia, nausea, fatigue, alopecia, thrombocytopenia, peripheral neuropathy
  • Subcutaneous form additionally: injection site reactions (4.5%)
  • Immune-mediated adverse reactions (e.g. pneumonitis, hepatitis, colitis, endocrinopathies)

Interactions

  • No metabolic drug interactions expected (cleared by catabolism)
  • Avoid systemic corticosteroids or immunosuppressants before starting; they may be used afterwards to treat immune-mediated reactions

Pregnancy and breastfeeding

  • No data in pregnant women; mechanism of action suggests potential foetal harm, including increased rates of abortion or stillbirth
  • Women of childbearing potential must use effective contraception during and for 5 months after treatment

Summary of the official product information, written with AI (Claude, Anthropic) on 2026-10-28. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Package leaflet, verbatim

Package leaflet for patients →

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

EU – centrally authorised (all member states)

  • TecentriqRoche Registration GmbH · EMEA/H/C/004143

Source: European Medicines Agency (EMA), product information

Turkey

  • TecentriqROCHE MÜSTAHZARLARI SAN.A.Ş. · 2 register entries

Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16

Brand names in 3 more European countries
Iceland
Tecentriq
Liechtenstein
Tecentriq
Norway
Tecentriq

EMA – Article 57 product data (EU/EEA), 2026-10-28

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Other substances in the same group

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. European Medicines Agency. Tecentriq – EPAR, Product Information (OF THE TEXT Detailed information on this medicinal product i). 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf
  2. TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85

Editorial: Medelix editorial team · last updated 2026-10-27 · How these pages are made · Report an error

Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.